Chardan Capital Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK)

Chardan Capital restated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK - Free Report) in a report published on Wednesday morning,Benzinga reports. Chardan Capital currently has a $24.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the company. HC Wainwright lifted their target price on Stoke Therapeutics from $35.00 to $47.00 and gave the stock a "buy" rating in a report on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $23.00.

Stoke Therapeutics Price Performance

NASDAQ STOK traded down $0.41 during trading on Wednesday, hitting $8.33. The company's stock had a trading volume of 1,043,493 shares, compared to its average volume of 875,682. The company has a market cap of $441.24 million, a PE ratio of -3.97 and a beta of 0.95. The business's 50 day simple moving average is $10.62 and its 200-day simple moving average is $12.32. Stoke Therapeutics has a fifty-two week low of $5.21 and a fifty-two week high of $17.58.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,666 shares of the business's stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the completion of the transaction, the general counsel now directly owns 21,476 shares of the company's stock, valued at approximately $292,288.36. The trade was a 38.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Barry Ticho sold 10,000 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the transaction, the insider now directly owns 51,277 shares of the company's stock, valued at $618,913.39. The trade was a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,849 shares of company stock valued at $809,421. 11.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Mesirow Financial Investment Management Inc. purchased a new stake in shares of Stoke Therapeutics in the third quarter valued at approximately $192,000. Los Angeles Capital Management LLC increased its position in shares of Stoke Therapeutics by 54.3% in the third quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company's stock valued at $1,266,000 after buying an additional 36,240 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Stoke Therapeutics in the third quarter valued at approximately $160,000. Charles Schwab Investment Management Inc. increased its position in shares of Stoke Therapeutics by 9.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company's stock valued at $3,885,000 after buying an additional 26,870 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Stoke Therapeutics by 1,589.7% in the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company's stock valued at $936,000 after buying an additional 71,647 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.